Emergent BioSolutions Inc.
EBS
$10.09
-$0.40-3.81%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 851.60M | 965.40M | 1.04B | 1.13B | 1.10B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 851.60M | 965.40M | 1.04B | 1.13B | 1.10B |
| Cost of Revenue | 440.20M | 680.20M | 737.00M | 828.20M | 871.10M |
| Gross Profit | 411.40M | 285.20M | 306.60M | 297.30M | 231.10M |
| SG&A Expenses | 234.00M | 267.30M | 299.40M | 328.10M | 331.20M |
| Depreciation & Amortization | 65.10M | 65.20M | 65.10M | 65.00M | 65.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 739.30M | 1.01B | 1.10B | 1.22B | 1.27B |
| Operating Income | 112.30M | -47.30M | -57.90M | -95.80M | -165.10M |
| Income Before Tax | 190.70M | -62.30M | -142.90M | -169.80M | -578.10M |
| Income Tax Expenses | 51.20M | 69.30M | 47.70M | 39.00M | 8.90M |
| Earnings from Continuing Operations | 139.50 | -131.60 | -190.60 | -208.80 | -587.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 139.50M | -131.60M | -190.60M | -208.80M | -587.00M |
| EBIT | 112.30M | -47.30M | -57.90M | -95.80M | -165.10M |
| EBITDA | 211.10M | 56.10M | 47.70M | 13.20M | -54.90M |
| EPS Basic | 2.61 | -2.55 | -3.63 | -4.00 | -11.25 |
| Normalized Basic EPS | 0.66 | -1.33 | -2.31 | -2.70 | -3.02 |
| EPS Diluted | 2.45 | -2.71 | -3.73 | -4.11 | -11.25 |
| Normalized Diluted EPS | 0.61 | -1.39 | -2.31 | -2.70 | -3.02 |
| Average Basic Shares Outstanding | 215.90M | 214.30M | 212.10M | 209.80M | 208.50M |
| Average Diluted Shares Outstanding | 221.30M | 219.70M | 214.60M | 212.30M | 208.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |